Retatrutide vs. Ozempic: Inside the New Head-to-Head Trial

Eli Lilly's experimental drug retatrutide produced more than twice the average weight loss of Ozempic in a late-stage diabetes trial, the company reported on October 28. More participants taking retatrutide also stopped treatment because of adverse events. Lilly's announcement

Ozempic is already an approved medicine. Retatrutide is not. For the experimental drug, a comparison with an established treatment is a consequential test: producing a larger change in weight is one hurdle; showing that people can tolerate treatment is another.

This report concerns clinical-trial medicines, not NuLab laboratory products. Research-use-only materials are not intended for human use.

What the trial found

The study, TRANSCEND-T2D-2, enrolled adults whose type 2 diabetes was not adequately controlled with metformin, with or without another medicine called an SGLT2 inhibitor. Participants were randomly assigned to treatment, and both they and the researchers knew which drug they received. Trial record

Lilly reported these results from 1,298 participants at 80 weeks:

Average body-weight reduction

• Retatrutide 9 mg group: 19.5%
• Retatrutide 12 mg group: 20.9%
• Ozempic 2 mg group: 9.4%

Average A1C reduction, percentage points

• Retatrutide 9 mg group: 2.2
• Retatrutide 12 mg group: 2.2
• Ozempic 2 mg group: 1.8

Stopped treatment because of adverse events

• Retatrutide 9 mg group: 4.8%
• Retatrutide 12 mg group: 7.9%
• Ozempic 2 mg group: 2.7%

Amounts identify study groups, not dosing recommendations. A1C measures average blood glucose.

Nausea, diarrhea and vomiting were among the reported adverse events. Altered or unpleasant sensations were also reported more often with retatrutide. Results and safety summary

For all the attention on weight, this was a study of people with diabetes. That distinction matters: it cannot tell us whether the same gap would appear in people without the disease. Nor was it a comparison with every formulation or use of semaglutide, the active ingredient in Ozempic.

Why retatrutide is different

Ozempic acts on the GLP-1 receptor, one of the body's hormone-signaling systems involved in blood-sugar regulation and appetite. Retatrutide is designed to act on three: GLP-1, GIP and glucagon. It is one molecule with three targets, not a mixture of three drugs. Ozempic prescribing information · Lilly's retatrutide overview

The name sometimes attached to retatrutide online, “GLP-3,” obscures that distinction. There is no GLP-3 receptor behind the drug's three-way action. The scientific term is a triple agonist. Lilly's explanation of the terminology

What the headline numbers leave out

Lilly's weight and blood-sugar figures estimate what would happen if participants stayed on their assigned treatment without adding prolonged extra diabetes medication. They are not a simple average of everyone's experience, including those who stopped. The company plans to publish the full findings in a peer-reviewed journal. Lilly's analysis notes

Both questions matter in a chronic condition: how well a medicine works when treatment continues, and what happens when people stop or need another medicine. FDA's statistical guidance recognizes these as different ways of assessing a treatment. FDA guidance

Among the questions left for the full report are how consistent the results were across different groups and how the benefits compare with the complete safety findings. For now, the public account comes primarily from the company developing the drug.

Where FDA approval stands

Retatrutide is not FDA approved. As of October 29, 2026, it remains investigational. FDA says it has not been found safe and effective for any condition and cannot be used in compounding under federal law. FDA's retatrutide statement

It is also absent from the six-peptide HHS policy announced this month. That announcement concerns a separate, conditional approach to pharmacy compounding; it does not authorize retatrutide. NuLab's HHS policy report

For readers following retatrutide's earlier Phase 3 results, the new comparison is another development milestone, not a change in access. Lilly has not established a confirmed launch date in its current public overview. Availability still depends on clinical development and regulatory review. Lilly's availability update

NuLab products are intended strictly for laboratory research use only and are not for human or animal consumption. This article provides research reporting, not medical, dosing, administration or compounding guidance.